Drug – bio-affecting and body treating compositions – Whole live micro-organism – cell – or virus containing – Genetically modified micro-organism – cell – or virus
Reexamination Certificate
2007-10-02
2007-10-02
Whiteman, Brian (Department: 1635)
Drug, bio-affecting and body treating compositions
Whole live micro-organism, cell, or virus containing
Genetically modified micro-organism, cell, or virus
Reexamination Certificate
active
11166234
ABSTRACT:
The invention provides methods of treating neoplasia using combinations of target cell-specific replication competent adenoviral vectors and chemotherapy, radiation therapy or combinations thereof. The adenoviral vectors are target cell-specific for the particular type of neoplasia for which treatment is necessary and the combination with the chemotherapy and/or radiation leads to synergistic treatment over existing adenoviral therapy or traditional chemotherapy and radiation therapy.
REFERENCES:
patent: 5302698 (1994-04-01), Morinaga et al.
patent: 5698443 (1997-12-01), Henderson et al.
patent: 5747469 (1998-05-01), Roth et al.
patent: 5776743 (1998-07-01), Frisch
patent: 5801029 (1998-09-01), McCormick
patent: 5846945 (1998-12-01), McCormick
patent: 5871726 (1999-02-01), Henderson et al.
patent: 5891690 (1999-04-01), Massie
patent: 5998205 (1999-12-01), Hallenbeck et al.
patent: 6197293 (2001-03-01), Henderson et al.
patent: 6395712 (2002-05-01), Hung et al.
patent: 6428968 (2002-08-01), Molnar-Kimber et al.
patent: 6432700 (2002-08-01), Henderson et al.
patent: 6436394 (2002-08-01), Henderson et al.
patent: 6521602 (2003-02-01), Patel et al.
patent: 6551587 (2003-04-01), Hallenbeck et al.
patent: 6617438 (2003-09-01), Beigelman et al.
patent: 6638762 (2003-10-01), Chang et al.
patent: 6676935 (2004-01-01), Henderson et al.
patent: 6911200 (2005-06-01), Yu et al.
patent: 2003/0044383 (2003-03-01), Henderson et al.
patent: 2003/0068307 (2003-04-01), Yu et al.
patent: 2003/0091538 (2003-05-01), Henderson et al.
patent: 2003/0104624 (2003-06-01), Clarke et al.
patent: 2003/0152553 (2003-08-01), Little et al.
patent: 98 07380 (1998-11-01), None
patent: 02546 (2000-03-01), None
patent: WO95/19434 (1995-07-01), None
patent: WO97/01358 (1997-01-01), None
patent: WO97/10007 (1997-03-01), None
patent: WO98/29555 (1998-07-01), None
patent: WO98/35554 (1998-08-01), None
patent: WO98/37189 (1998-08-01), None
patent: WO98/39464 (1998-09-01), None
patent: WO98/39465 (1998-09-01), None
patent: WO 98/39465 (1998-09-01), None
patent: WO98/39466 (1998-09-01), None
patent: WO 98/39467 (1998-09-01), None
patent: WO98/39467 (1998-09-01), None
patent: WO99/06576 (1999-02-01), None
patent: WO99/25860 (1999-05-01), None
patent: WO99/59604 (1999-11-01), None
patent: WO 00/15820 (2000-03-01), None
patent: WO 00/39319 (2000-07-01), None
Abe et al., “Transcriptional Regulation of DF3 Gene Expression in Human MCF-7 Breast Carcinoma Cells,” Journal Cell Physiology, vol. 143, pp. 226-231, 1990.
Abe et al., “Characterization of cis-acting elements regulating transcription of the human DF3 breast carcinoma-associated antigen (MUCI) gene,” PNAS, vol. 90, pp. 282-286, 1993.
Alfieri & Hahn, “An in Situ Method for Estimating Cell Survival in a Solid Tumor,” Cancer Research, vol. 38, pp. 3006-3011, 1978.
Aoe et al., “Effect of Docetaxel with Cisplatin or Vinorelbine on Lung Cancer Cell Lines,” Anticancer Reasearch, vol. 19, pp. 291-299, 1999.
Bailey et al., “Enteric Adenovirus Type 40: Expression of E1 B Proteins in Vitro and in Vivo,” Virology, vol. 193, pp. 631-641, 1993.
Bailey et al., “Cell Type Specific Regulation of Expression from the Ad40 E1B Promoter in Recombinant Ad5/Ad40 Viruses,” Virology, vol. 202, pp. 695-706, 1994.
Behringer et al., “Dwarf mice produced by genetic ablation of growth hormone-expressing cells,” Genes & Development, vol. 2, pp. 453-461, 1988.
Berkner et al., “Generation of adenovirus by transfection of plasmids,” Nucleic Acids Research, vol. 11(17), pp. 6003-6020, 1983.
Bernstein et al., “PGDF2/c-sis mRNA Leader Contains a Differentiation-linked Internal Ribosomal Entry Site (D-IRES),” Journal of Biological Chemistry, vol. 272(14), pp. 9356-9362, 1997.
Bett et al., “Packaging Capacity and Stability of Human Adenovirus Type 5 Vectors,” Journal of Virology, vol. 67(10), pp. 5911-5921, 1993.
Bett et al., “An efficient and flexible system for construction of adenovirus vectors with insertions or deletions in early regions 1 and 3,” PNAS, vol. 91, pp. 8802-8806, 1994.
Blackwood et al., “Going the Distance: A Current View of Enhancer Action,” Science, vol. 281, pp. 60-63, 1998.
Blagosklonny et al., “Efficacy of Microtubule-Active Drugs Followed by Ketoconazole in Human Metastatic Prostate Cancer Cell Lines,” Journal of Urology, vol. 163, pp. 1022-1026, 2000.
Borman et al., “Sequences within the poliovirus internal ribosome entry segment control virual RNA synthesis,” EMBO Journal, vol. 13(13), pp. 3149-3157, 1994.
Braun et al., “Immunogenic Duplex Nucleic Acids are Nuclease Resistant,” Journal of Immunology, vol. 141, pp. 2084-2089, 1988.
Bridge et al., “Redundant Control of Adenovirus Late Gene Expression by Early Region 4,” Journal of Virology, vol. 63(2), pp. 631-638, 1989.
Brown et al., Translation of Poliovirus RNA in Vitro: Changes in Cleavage Pattern and Initiation Sites by Ribosomal Salt Wash, Virology, vol. 97, pp. 396-405, 1979.
Bunn & Poyton, “Oxygen Sensing and Molecular Adaptation to Hypoxia,” Physiol. Review, vol. 76(3), pp. 839-885, 1996.
Butterfield et al., “Cloning and analysis of MART-1//Melan-A human melanoma antigen promoter regions,” Gene, vol. 191, pp. 129-134, 1997.
Cannio et al., “A cell-type specific and enhancer-dependent silencer in the regulation of the expression of the human urokinase plasminogen activator gene,” Nucleic Acids Research, vol. 19(9), pp. 2303-2308, 1991.
Chahinian et al., “Effectiveness of Cisplatin, Paclitaxel, and Suramin Against Human Malignant Mesothelioma Xenografts in Athymic Nude Mice,” Journal of Surgical Oncology, vol. 67, pp. 104-111, 1998.
Charlesworth et al., “Detection of a Prostate-Specific Protein, Human Glandular Kallikrein (hK2), In Sera of Patients with Elevated Prostate-Specific Antigen Levels,” Urology, vol. 49(3), pp. 487-493, 1997.
Chaturvedi et al., “Stabilization of triple-stranded oligonucleotide complexes: use of probes containing alternating phosphodiester and stereo-uniform cationic phosphoramidate linkages,” Nucleic Acids Research, vol. 24(12), pp. 2318-2323, 1996.
Chen et al., “Pre-Existent Adenovirus Antibody Inhibits Systemic Toxicity and Antitumor Activity of CN706 in the Nude Mouse LNCaP Xenograft Model: Implications and Proposals for Human Therapy,” Human Gene Therapy, vol. 11, pp. 1553-1567, 2000.
Creane et al., “Radiobiological effects of docetaxel (Taxotere): a potential radiation sensitizer,” Int. Journal Radiation Biology, vol. 75(6), pp. 731-737, 1999.
Dachs & Stratford, “The molecular response of mammalian cells to hypoxia and the potential for exploitation in cancer therapy,” British Journal Cancer, vol. 74 (Supplement XXVII):S126-S132, 1996.
Darson et al., “Human Glandular Kallikrein 2 (hK2) Expression in prostatic Intraepithelial Neoplasia and Adenocarcinoma: A Novel Prostate Cancer Marker,” Urology, vol. 49, pp. 857-862, 1997.
Denizot, “Rapid colorimetric assay for cell growth and survival Modifications to the tetrazolium dye procedure giving improved sensitivity and reliability,” Journal of Immunol Methods, vol. 89, pp. 271-277, 1986.
Dodd et al., “Characterization and Cloning of Rat Dorsal Prostate mRNAs,” Journal of Biological Chemistry, vol. 258(17), pp. 10731-10737, 1983.
Dorner et al., “In Vitro Translation of Poliovirus RNA: Utilization of Internal Initiation Sites in Reticulocyte Lysate,” Journal of Virology, vol. 50(2), pp. 507-514, 1984.
Duke et al., “Sequence and Structural Elements That Contribute to Efficient Encephalomyocarditis Virus RNA Translation,” Journal of Virology, vol. 66(3), pp. 1602-1609, 1992.
Felgner & Ringold, “Cationic liposome-mediated transfection,” Nature, vol. 337, pp. 387-388, 1989.
Flint, “Regulation of Ade
Chen Yu
Henderson Daniel R.
Yu De-Chao
Cell Genesys Inc.
Chen Teresa A.
Haley Jr. James F.
Ropes & Gray LLP
Whiteman Brian
LandOfFree
Methods of treating neoplasia with combinations of target... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods of treating neoplasia with combinations of target..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods of treating neoplasia with combinations of target... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3896045